Skip to content

Early Evaluation of Vascular Calcification in Patients with Chronic Kidney Disease and Significance of Medicinal Carbon Tablet Intervention

Effect of Oral Medicinal Carbon Tablets on Hyperphosphatemia and Vascular Calcification in Patients with Chronic Renal Disease Stages 3 to 4

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018963
Enrollment
Unknown
Registered
2018-10-19
Start date
2016-01-01
Completion date
Unknown
Last updated
2018-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Case series:Oral medicinal carbon tablets

Sponsors

Qianfoshan Hospital Shandong
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged above 18 years old; 2. Clinical diagnosis (history, serum creatinine, renal ultrasonography, laboratory tests, etc.) was 3-4 cycles of chronic kidney disease, and the creatinine clearance rate was 15-60 ml/(min.1.73 m2) calculated according to the Cockcroft-Gault formula; 3. Kidney replacement therapy (peritoneal dialysis, hemodialysis, or kidney transplant) not performe; 4. It is generally in good condition, has a good understanding of its own condition and physical condition, has insight, and can communicate well with people; 5. Voluntarily join the study to understand the significance of the trial and the indicators that need to be measured and to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe infections: There are clinical manifestations such as fever, cough, sputum, sore throat, abdominal pain, diarrhea, sputum and other skin and soft tissue infections, and the blood white blood cell count exceeds the normal range (10 × 10^9/L); 2. Severe cardiovascular disease: including grade 3 or more of chronic cardiac insufficiency and various arrhythmias; 3. Severe anemia: Hemoglobin less than 60g/L; 4. Obvious hypoproteinemia: albumin below 30g/L; 5. Oncological evidence: A tumor or clinical manifestations and tumor markers have been identified as suggestive of a tumor; 6. Patients with severe cognitive impairment or who do not want to participate; 7. Patients have neuromuscular disorders, inflammatory bowel disease, and functional gastrointestinal disorders.

Design outcomes

Primary

MeasureTime frame
Phosphorus concentration;

Countries

China

Contacts

Public ContactZunsong Wang

Qianfoshan Hospital Shandong

wzsong3@163.com+86 15966608835

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026